Neuroscience research program
Parkinson's Disease
Research
We study the biology behind
tremor and motor decline — from poly-glutamine acid pathways to
wearable technology — and turn those findings into therapies
that quiet the disease’s effects.
1st
2nd
3rd
Prize, Cambridge Conf.
research highlights
Where the work is headed,
and who's behind it
“An international research collaboration presented findings at the Cambridge Conference — one of several exchanges building a shared, cross-institutional picture of Parkinson’s.”
Fig. 01 — Research Footage
01 Cross-institutional collaboration
Joint work with partner labs to compare methods and pool patient
data across sites.
02 Cambridge Conference presentation
Findings on disease mechanisms presented to the international
research community.
03 Biotech partnership
Applying lab findings toward early-stage, symptom-reducing device
design.
Research Publication
Recognized work, shared
with the field
Two collaborations that moved this research from the lab bench to the wider research community.
Add Your Heading Text Here
First Prize · Cambridge Conference
International Research Collaboration Wins First Prize
International Research Collaboration Wins First Prize
Add Your Heading Text Here
SciTech International Collaboration
Extending the Research Through Biotech Partnership
Partnering with biotech researchers to translate lab results into applied, patient-facing tools.
Poly-Q-Glutamic Acid & Parkinson’s Disease
What the research found —
and why it matters
| Study | Key Findings | Research Impact |
|---|---|---|
| Poly-Glutamine Cytotoxicity | Elevated poly-glutamine acid correlates with accelerated neuron degeneration in tested models. | Opens a target for biomarker screening. |
| Cross-Model Comparison | Effects replicated across independent lab models. | Supports moving toward therapeutic trials. |
| Symptom Correlation | Marker levels track with motor symptom severity over time. | Informs the design of symptom monitoring tools. |
Future Plans
Expand the collaboration
Bring additional institutions into the shared data pool to test findings at larger scale.
Clinical trial design
Translate poly-glutamine acid findings into a formal trial protocol.
Device pilot program
Integrate the wearable monitoring system into a real patient pilot and refine the design based on early feedback.
Parkinson's Team
Founder/CEO
Advisor
Angel Investor
Advisor
Researcher